Resistance profiles in patients with viral rebound on potent antiretroviral therapy

Journal of Infectious Diseases

Volumn 181, Issue 3, 2000, Pages 1143-1147

  Lepri, Alessandro Cozzi ^a   Sabin, Caroline A ^a   Staszewski, Schlomo ^b   Hertogs, Kurt ^c   Müller, Axel ^b   Rabenau, Holger ^b   Phillips, Andrew N ^a   Miller, Veronica ^b,d  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b GOETHE UNIVERSITY   (Germany)

^c Virco BVBA   (Belgium)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; DRUG POTENCY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; RECURRENT DISEASE; VIRUS LOAD;

EID: 0034127545     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315301     Document Type: Article

References (15)

1. 1. Palella FJ Jr. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
2. 2. Deeks SG, Grant RM, Beatty, GW, Horton C, Detmer J, Eastman S. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS 1998; 12:F97-102.
3. 3. Young B, Johnson S, Bahktiari M, et al. Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. J Infect Dis 1998; 178:1497-501.
4. 4. Deeks SG, Parkin N, Petropoulos, et al. Correlation of baseline phenotypic drug susceptibility with 16 week virologic response in a pilot combination therapy study in HIV-infected patients who failed indinavir therapy [abstract 53]. 2d International Workshop on Drug Resistance & Treatment Strategies (Lake Maggiore, Italy). London: International Medical Press, 1998.
5. 5. Montaner JSG, Harrigan R, Jahnke N, et al. Multi-drug rescue therapy (MDRT) following failure to multiple regimens: preliminary results [abstract]. AIDS 1998; 12(Suppl 4):S18.
6. 6. Patick AK, Zhang M, Hertogs K, et al. Correlation of virological response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfinavir in the US expanded access program [abstract 57]. 2d International Workshop on Drug Resistance & Treatment Strategies (Lake Maggiore, Italy). London: International Medical Press, 1998.
7. 7. Havlir DV, Petropulos CJ, Hellmann NS, et al. Evolution of drug resistance associated with loss of viral suppression in patients treated with Indinavir (IDV), lamivudine (3TC) and zidovudine (ZDV) [abstract 74]. 2d International Workshop on Drug Resistance & Treatment Strategies (Lake Maggiore, Italy). London: International Medical Press, 1998.
8. 8. De Pasquale MP, Murphy R, Kurtikes D, et al. Resistance during early virological rebound on amprenavir plus zidovudine plus lamivudine triple therapy or amprenavir monotherapy in ACTG protocol 347 [abstract 71]. 2d International Workshop on Drug Resistance & Treatment Strategies (Lake Maggiore, Italy). London: International Medical Press, 1998.
9. 9. Hertogs K, de Béthune MP, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998; 42:269-76.
10. 10. Katzenstein DA, Shafer RW, Bosch RJ, Albrecht M, Hammer SM. Reverse transcriptase and protease genotypes of nucleoside-experienced subjects with virological failure of nelfinavir or efavirenz [abstract 84]. 2d International Workshop on Drug Resistance & Treatment Strategies (Lake Maggiore, Italy). London: International Medical Press, 1998.
11. 11. Miller V, Rottman C, Hertogs K, et al. Mega-HAART, resistance and drug holidays [abstract]. Antiviral Ther 1999; 4(Suppl 1):27-8.
12. 12. Mayers DL, Gallahan DL, Marting GL, et al. Drug resistance genotypes from plasma virus of HIV-infected patients failing combination drug therapy [abstract]. Antiviral Ther 1997; 2(Suppl 5):72.
13. 13. Johnson VA, Nail CD, Hazelwood JD, et al. Multidrug-resistant HIV-1 isolates from patients with rising plasma viral burden during double or triple combination therapy in clinical practice [abstract]. Antiviral Ther 1997; 2(Suppl 5):72.
14. 14. Hellmann N, Johnson P, Petropoulos C. Validation of the performance characteristics of a novel, rapid phenotypic drug susceptibility assay, PhenoSense HIV [abstract]. Antiviral Ther 1999; 4(Suppl 1):34.
15. 15. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353: 2195-9.